---
schema_version: "secwatch.filing_event.v1"
accession: "0001575872-23-000150"
form_type: "8-K/A"
ticker: "SMNR"
cik: "0001913577"
company_name: "Semnur Pharmaceuticals, Inc."
filed_at: "2023-01-26T23:59:59+00:00"
generated_at: "2026-06-20T08:33:31.784729+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Denali Capital Acquisition Corp. enters merger agreement with Longevity Biomedical

## Summary
- Denali entered into a merger agreement with Longevity Biomedical, Inc. on Jan 25, 2023, with a total enterprise value of $128 million.
- Under the merger, Denali SPAC Holdco will become New PubCo, renamed Longevity Biomedical, expected to list on NASDAQ under ticker LBIO.
- The transaction requires approval by Denali shareholders and other conditions, including net tangible assets of at least $5,000,001 after redemptions.
- Sponsor and Investor FutureTech Capital agreed to purchase 625,000 Class B units for $5 million, with $2 million already paid.

## SEC filing metadata
- accession: 0001575872-23-000150
- form_type: 8-K/A
- ticker: SMNR
- cik: 0001913577
- company_name: Semnur Pharmaceuticals, Inc.
- filed_at: 2023-01-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1913577/000157587223000150/0001575872-23-000150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1913577/000157587223000150/deca-20230125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001575872-23-000150
- JSON: https://secwatch.observer/filing/0001575872-23-000150.json
- Plain text: https://secwatch.observer/filing/0001575872-23-000150.txt

## Key facts
- Material Agreements
  Semnur Pharmaceuticals, Inc. entered into Agreement and Plan of Merger with Longevity Biomedical, Inc., Denali SPAC Holdco, Inc., Denali SPAC Merger Sub, Inc., Longevity Merger Sub, Inc., and Bradford A. Zakes, solely in the capacity as seller representative valued at $128,000,000 (effective 2023-01-25).
  - Action: entry
  - Agreement: merger
  - Counterparty: Longevity Biomedical, Inc., Denali SPAC Holdco, Inc., Denali SPAC Merger Sub, Inc., Longevity Merger Sub, Inc., and Bradford A. Zakes, solely in the capacity as seller representative
  - Value: $128,000,000
  - Effective: 2023-01-25
  source text: On January 25, 2023, Denali entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among Denali, Longevity Biomedical, Inc., a Delaware corporation (“ Company ”), Denali SPAC Holdco, Inc., a Delaware corporation and direct, wholly owned subsidiary of Denali (“ New PubCo ”), Denali SPAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of New PubCo (“ Denali Merger Sub ”), Longevity Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of New PubCo (“ Longevity Merger Sub ”), and Bradford A. Zakes, solely in the capacity as seller representative.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1913577/000157587223000150/0001575872-23-000150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.